Adina M Hughes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5129780/publications.pdf

Version: 2024-02-01

10	511	6	7
papers	citations	h-index	g-index
10	10	10	1010
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer. Clinical Cancer Research, 2018, 24, 5153-5164.	7.0	126
2	Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically. Molecular Cancer Therapeutics, 2020, 19, 13-25.	4.1	104
3	Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery., 2019, 7, 328.		65
4	PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity. , 2018, 6, 158.		62
5	ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib. Cancer Research, 2022, 82, 1140-1152.	0.9	52
6	Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity. Oncolmmunology, 2018, 7, e1458810.	4.6	30
7	<i>STAT3</i> Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti–PD-L1. Clinical Cancer Research, 2020, 26, 6335-6349.	7.0	26
8	Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer., 2022, 10, e003892.		26
9	Modeling Dose and Schedule Effects of AZD2811 Nanoparticles Targeting Aurora B Kinase for Treatment of Diffuse Large B-cell Lymphoma. Molecular Cancer Therapeutics, 2019, 18, 909-919.	4.1	13
10	Macrophage Activation Status Rather than Repolarization Is Associated with Enhanced Checkpoint Activity in Combination with PI3 \hat{K}^3 Inhibition. Molecular Cancer Therapeutics, 2021, 20, 1080-1091.	4.1	7